Not checked for notices yet.
The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments
Samson Rebecca S, Tozer Daniel J, Wheeler-Kingshott Claudia AM and 18 more
Trials · 2011
Cited by papers we hold 3
- Mesenchymal stem cells and immunomodulation: current status and future prospects · 2016No notice
- Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells · 2013No notice
- Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study · 2012No notice
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.